cardiology
Medicines

News in Brief: Selexipag on PBS; IHD rates decline; Active ingredient prescribing

Selexipag listed on PBS for PAH The oral therapy selexipag (Uptravi) is available on the PBS from 1 February for the treatment of people with pulmonary artery hypertension (PAH) as combination therapy. The selective, prostacyclin receptor agonist is indicated as sequential add-on therapy in combination with an endothelin receptor antagonist (ERA) and/or phosphodiesterase type 5 ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic